[HTML][HTML] Avapritinib Inhibitor
J Krawczyk, N Keane, R Swords… - Expert Opin …, 2013 - avapritinibinhibitor.com
Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models,
perifosine has an independent cytotoxic potential but also synergizes well with other …
perifosine has an independent cytotoxic potential but also synergizes well with other …
Perifosine–a new option in treatment of acute myeloid leukemia?
J Krawczyk, N Keane, R Swords… - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models,
perifosine has an independent cytotoxic potential but also synergizes well with other …
perifosine has an independent cytotoxic potential but also synergizes well with other …
[HTML][HTML] Plc Signaling
J Krawczyk, N Keane, R Swords… - Expert Opin. Investig …, 2013 - plcsignaling.com
Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models,
perifosine has an independent cytotoxic potential but also synergizes well with other …
perifosine has an independent cytotoxic potential but also synergizes well with other …
[引用][C] Oncology Drug Reference Sheet: Avapritinib.
KB LeFebvre - ONS Voice, 2022 - search.ebscohost.com
A missed dose can be taken up to eight hours before the next dose is due. A voinited dose
should not be repeated; instead, patients should wait and take the next dose on schedule …
should not be repeated; instead, patients should wait and take the next dose on schedule …
Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity
PG Richardson, C Eng, J Kolesar… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical
development for treatment of colorectal cancer (CRC, in combination with capecitabine) and …
development for treatment of colorectal cancer (CRC, in combination with capecitabine) and …
Perifosine: update on a novel Akt inhibitor
JJ Gills, PA Dennis - Current oncology reports, 2009 - Springer
Abstract The PI3K/Akt/mTOR pathway is aberrantly active in most human cancers and
contributes to cell growth, proliferation, and survival. Akt is a nodal regulator of cellular …
contributes to cell growth, proliferation, and survival. Akt is a nodal regulator of cellular …
Phase I study of veliparib in combination with gemcitabine
Abstract Background Veliparib (ABT-888) is an oral PARP inhibitor expected to increase
gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose …
gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose …
[HTML][HTML] Avapritinib Inhibitor
B Jakstys, M Jakutaviciute, D Uzdavinyte… - avapritinibinhibitor.com
Control of membrane permeability to exogenous compounds by membrane electroporation
can lead to cell death, which is related to permanent membrane damage, oxidation stress …
can lead to cell death, which is related to permanent membrane damage, oxidation stress …
[HTML][HTML] Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.
R Voltan, C Celeghini, E Melloni, P Secchiero… - British journal of …, 2009 - sfera.unife.it
Perifosine, which belongs to the novel class of antitumoral agents alkylphospholipids, is
currently undergoing phase II clinical evaluation (van Blitterswijk & Verheij, 2008). Although …
currently undergoing phase II clinical evaluation (van Blitterswijk & Verheij, 2008). Although …
[HTML][HTML] Phase I trial of the oral poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888, V) combined wtih topoecan (T) and carboplatin (C) for adults with …
Abstract 3634 PARP is activated in response to DNA single strand (SS) breaks and is pivotal
to the base excisional repair pathway for chemotherapy-damaged DNA. The orally …
to the base excisional repair pathway for chemotherapy-damaged DNA. The orally …